The number of private equity-driven deals in gastroenterology — including add-on, platform and growth deals — decreased by half between 2022 and 2023.
|
Type of Deal |
2020 |
2021 |
2022 |
2023 |
|
Total |
15 |
34 |
26 |
13 |
|
Add-on |
12 |
31 |
22 |
10 |
|
Platform |
3 |
1 |
2 |
1 |
|
Growth |
N/A |
2 |
2 |
2 |
